An academic monocenter study assessing the safety and efficacy of Lucentis (ranizumab 0.3 mg) administered in conjunction with photodynamic therapy with Visudyne in patients with occult or predominantly classic subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Latest Information Update: 31 Jan 2023
At a glance
- Drugs Ranibizumab (Primary) ; Verteporfin (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation
- Focus Adverse reactions
- 31 Jan 2023 New trial record